The glucagon-like peptide 1 receptor (GLP-1R) agonist semaglutide is effective for the
treatment of obesity and type 2 diabetes mellitus (T2DM). The purpose of this article is to …

Background More women than men have heart failure with preserved ejection fraction
(HFpEF). Objectives The purpose of this study was to assess baseline characteristics and …

People with overweight or obese have an increased risk of developing heart failure and
atrial fibrillation but treatment strategies for this group of patients remain not established …

Background Semaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, has
shown promise in weight management and cardiovascular outcomes in other populations …

Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Introduction: Obesity-related heart failure in patients is often associated with high symptom
burden. However, no treatments have been proven to specifically target obesity-related …

Semaglutide in obesity-related heart failure with preserved ejection fraction Page 1
Semaglutide in obesity-related heart failure with preserved ejection fraction Semaglutide versus …

Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

Heart failure with preserved ejection fraction (HFpEF) currently represents the majority of all
heart failure cases in the community. Glucagon-like peptide-1 agonists represent a class of …

Background STEP-HFpEF, a 52 week trial conducted in patients with obesity phenotype of
heart failure with preserved ejection fraction (HFpEF) and no type 2 diabetes, examined the …